Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.

Theranostics - 1 Jan 2020

Liu Shuli, Wang Yang, Han Yong, Xia Weiya, Zhang Ling, Xu Shengming, Ju Houyu, Zhang Xiangkai, Ren Guoxin, Liu Liu, Ye Weimin, Zhang Zhiyuan, Hu Jingzhou

Abstract excerpt

Rationale: The oncogenesis of head and neck squamous cell carcinoma (HNSCC) is believed to result from oncogene activation and tumor suppressor inactivation. Here, we identified a new oncogenic role for the EREG gene in HNSCC. Methods: The TCGA database and immunohistochemistry assay were used to analyze expression of EREG in HNSCC tissues. Immunoblotting was performed to identify the EGFR-mediated pathways...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knockdown Techniques

Share to Head and Neck Neoplasms

Share to Proto-Oncogene Proteins c-myc

Share to Squamous Cell Carcinoma of Head and Neck

Share to Up-Regulation

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32929368
DOI: 10.7150/thno.47176
PMCID: PMC7482801

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.PMID 32929368Read ↗

The Role of EREG/EGFR Pathway in Tumor Progression.Semantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.Semantic proximity Read ↗

Roles of E2F family members in the diagnosis and prognosis of head and neck squamous cell carcinomaSemantic proximity Read ↗

Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathwaySemantic proximity Read ↗

A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancerSemantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).Semantic proximity Read ↗

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read ↗

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.Semantic proximity Read ↗

Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Semantic proximity Read ↗

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.